{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-26-000025","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.475398+00:00","generated_at":"2026-05-15T08:37:45.616820+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intensity Therapeutics 2025 net loss $11.6M; cash $11.9M; TNBC trial pCR 71% vs 33%","bullets":["Net loss narrowed to $11.6M from $16.3M in 2024; R&D spend fell to $6.8M from $10.5M.","Cash and equivalents $11.9M at Dec 31, 2025; raised >$20M in 2025; runway into Q2 2027.","INVINCIBLE-4 TNBC trial: 5/7 (71.4%) pCR with INT230-6+SOC vs 2/6 (33%) SOC alone; fewer grade 3+ AEs.","INVINCIBLE-3 sarcoma trial paused in March 2025; 21 patients enrolled; restart depends on funding.","IT-01 study published in eBioMedicine: 75% disease control rate, median OS 11.9 months in refractory tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-26-000025","json":"https://secwatch.observer/filing/0001567264-26-000025.json","markdown":"https://secwatch.observer/filing/0001567264-26-000025.md","text":"https://secwatch.observer/filing/0001567264-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/0001567264-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/intensity-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:37:45.616820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcb498b0cd213faf33c48c4c96d726c607c53c3c","claim":"INTENSITY THERAPEUTICS, INC. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/0001567264-26-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}